Wednesday is the day markets have been bracing for all month: the Federal Reserve delivers its interest rate decision at 2 p.m. Eastern, with futures traders now pricing in roughly 90–92% odds of a quarter-point hike — the first since 2023. The 10-year Treasury yield already touched 5.045% intraday Tuesday, its highest level since 2007, and Chair Kevin Warsh’s press conference and updated “dot plot” will matter just as much as the rate decision itself. With no major earnings on the docket until Thursday, tomorrow’s action will hinge on how a handful of smaller, rate- and AI-sensitive names react to whatever the Fed decides. Skipping the obvious mega-caps, here are the 10 top stocks to watch tomorrow.
Stocks to Watch Tomorrow (Sept. 16, 2026):
1. Redwood Trust (RWT) | Trading Near $3.77 | The Purest Fed-Day Trade on the Board
A Mortgage REIT With Everything Riding on 2 p.m. Eastern
Few small-cap stocks are as directly exposed to tomorrow’s Fed decision as Redwood Trust, a mortgage REIT whose entire business model lives or dies by the interest-rate environment.
Full Data & Snapshot:
| Metric | Value |
|---|---|
| Recent Price | ~$3.77 |
| 52-Week Range | $4.19 – $6.97 (trailing-year data) |
| New Financing | $185M convertible senior notes, priced Sept. 11 |
| Latest Analyst Action | UBS cut target to $6.50 from $7 |
| Q3 2026 Dividend | $0.18/share declared |
Why It’s in Focus: Redwood priced an upsized $185 million convertible notes offering just days ago, adding fresh leverage to its balance sheet right as the 10-year yield hit a 19-year high. As a specialty mortgage finance company, Redwood’s origination volumes and book value are directly tied to where rates settle after tomorrow’s decision — making it one of the cleanest, most literal ways to trade the Fed outcome in the small-cap space.
Technicals: Resistance sits at $4.19–$4.50, the low end of the stock’s trailing 52-week range. Support sits at $3.50, just below current levels — a level that would represent fresh multi-month lows if broken.
Bull Case: A dovish surprise or even just a “one-and-done” signal in Wednesday’s dot plot could spark a sharp relief rally in a stock trading near depressed levels, and Redwood continues posting record mortgage-banking production despite the tough rate backdrop.
Bear Case: A confirmed hike paired with hawkish forward guidance would likely extend pressure on mortgage origination volumes sector-wide, and the fresh convertible debt raises questions about balance-sheet flexibility at current valuations.
Forecast: This is as close to a pure, binary Fed-decision trade as exists on this list — position sizing matters given how directly tomorrow’s outcome will move the stock in either direction.
2. IREN Limited (IREN) | Closed at $43.83 | The JPMorgan Upgrade Still Fighting the Tape
Will the Bulls or the Broader Selloff Win Out?
IREN enters tomorrow still digesting a stunning double-upgrade from JPMorgan even as broader AI-infrastructure sentiment continues to work against it.
Full Data & Snapshot:
| Metric | Value |
|---|---|
| Last Close | $43.83 |
| JPMorgan Price Target | $65 (up from $46) |
| Implied Upside | ~48% |
| FY2026 ARR Target | $4.0B (raised from $3.4B) |
| Analyst Consensus | Moderate Buy, $81.57 average target |
Why It’s in Focus: JPMorgan’s double upgrade to Overweight has yet to translate into sustained share-price strength, with the stock still trading well below the new $65 target as broader AI-slowdown sentiment and now Fed-decision jitters weigh on the entire neocloud sector. Tomorrow’s Fed outcome adds another layer: IREN’s massive planned 2027 capex ($25–$30 billion) makes it highly sensitive to the cost of future financing.
Technicals: Resistance sits at $49–$50, levels touched earlier this month. Support sits at $40–$41, recent consolidation lows — a break below could open a path toward the high $30s.
Bull Case: A $4 billion ARR target, an Nvidia partnership, and rising per-watt pricing power give IREN genuine fundamental momentum that a single Fed decision shouldn’t fundamentally alter.
Bear Case: With only about $1 billion of that $4 billion ARR currently operating, a hawkish Fed outcome that raises financing costs for the remaining buildout could meaningfully pressure the stock’s already-stretched capex plans.
Forecast: Watch whether IREN can finally decouple from broader sector sentiment post-Fed — a stock-specific bounce would validate the JPMorgan thesis, while continued weakness would suggest the market isn’t ready to separate IREN from the AI-slowdown narrative.
3. MARA Holdings (MARA) | Trading Near $11.00 | A Bitcoin Miner’s Double Fed Exposure
Rate Decisions Move Both Bitcoin and MARA’s Financing Costs
MARA Holdings faces a unique double exposure to tomorrow’s Fed decision: through Bitcoin’s own rate sensitivity and through the company’s own capital-intensive AI-pivot strategy.
Full Data & Snapshot:
| Metric | Value |
|---|---|
| Recent Price | ~$11.00 |
| JPMorgan Price Target | $11 (down from $13, Underweight reaffirmed) |
| Q2 2026 EPS | −$1.60 (vs. $0.35 expected) |
| 52-Week Range | $6.66 – $23.45 |
Why It’s in Focus: JPMorgan’s fresh Underweight reaffirmation on MARA — issued the same day it double-upgraded rival IREN — sets up an interesting real-time comparison heading into the Fed decision. Bitcoin itself tends to react sharply to rate surprises, and MARA’s still-unresolved strategic pivot toward AI infrastructure means the stock carries both crypto-market and capital-markets risk simultaneously tomorrow.
Technicals: Resistance sits at $12.00–$12.50, this week’s trading range. Support sits at $10.00, a psychological round-number level, with the 52-week low of $6.66 as a deeper floor.
Bull Case: Bitcoin trading near multi-month highs provides a fundamental offset to the equity-specific downgrade, and a dovish Fed surprise tends to be broadly supportive of crypto-adjacent names.
Bear Case: JPMorgan’s explicit preference for IREN’s execution over MARA’s strategy suggests real skepticism from a major bank, and a hawkish Fed outcome could pressure both Bitcoin prices and MARA’s financing costs simultaneously.
Forecast: Track MARA’s reaction relative to IREN’s tomorrow — a wide divergence in either direction would say a lot about which underlying thesis (AI infrastructure versus continued crypto-mining focus) the market is rewarding right now.
4. Super Micro Computer (SMCI) | Fell to $37.33 | An AI Server Maker Caught Between Two Storms
AI-Slowdown Fears Meet Fed-Decision Jitters
Super Micro Computer has dropped nearly 8% in a single session this week as fears over AI infrastructure spending compound uncertainty heading into tomorrow’s rate decision.
Full Data & Snapshot:
| Metric | Value |
|---|---|
| Last Close | $37.33 |
| Daily Move (Monday) | −7.19% |
| Market Cap | ~$26.34B |
| 52-Week Range | $19.48 – $58.78 |
| FY2027 Revenue Guidance | $65B–$72B |
Why It’s in Focus: SMCI shares dropped nearly 8% as renewed AI-spending concerns pressured the broader tech sector, with investors questioning whether hyperscalers might moderate the pace of AI infrastructure buildout following recent industry safety warnings. The stock’s high beta of nearly 3.0 means it tends to amplify both broader sector sentiment and any Fed-driven shift in risk appetite tomorrow.
Technicals: Shares have fallen roughly 19% over the past month, well underperforming the broader tech sector’s roughly 12% decline over the same window. Resistance sits at $40–$40.45, this week’s earlier trading range. Support sits at $35–$37, a level from recent consolidation.
Bull Case: A $60 billion-plus order book with 70% tied to AI infrastructure, alongside aggressive fiscal 2027 revenue guidance of $65–$72 billion, suggests the underlying demand story remains intact regardless of near-term sentiment swings.
Bear Case: Customer concentration at 28% of revenue, elevated inventory of $12.9 billion, and negative free cash flow amid rapid expansion all create real fundamental risk if AI capital spending genuinely decelerates.
Forecast: A stabilization above $37 tomorrow would suggest the stock has found a near-term floor; a break below that level alongside a hawkish Fed surprise could accelerate the month’s already-steep decline.
5. Telix Pharmaceuticals (TLX) | Fresh FDA Approval Just Landed
The Only Approved Brain-Cancer Imaging Drug in America
Telix Pharmaceuticals just cleared one of the biggest regulatory hurdles of its year, and tomorrow marks the market’s first full session to digest the news.
Full Data & Snapshot:
| Metric | Value |
|---|---|
| Approval Date | September 14, 2026 |
| Drug | Pixclara (floretyrosine F 18) |
| Indication | Glioma (brain cancer) PET imaging |
| Regulatory Exclusivity | 7-year legal monopoly on the indication |
| FY2026 Revenue Guidance | $950M–$970M (excludes Pixclara) |
Why It’s in Focus: The FDA approved Telix’s Pixclara, making it the first and only FDA-approved PET imaging drug for glioma in the United States — a market where clinical guidelines already recommend the underlying technology but no approved commercial product previously existed. Crucially, Telix’s current 2026 revenue guidance of $950–$970 million doesn’t include a single dollar of Pixclara sales, meaning any commercial traction represents pure upside layered on top of already-growing prostate-imaging revenue from Illuccix and Gozellix.
Technicals: With the approval landing after Sunday’s announcement, tomorrow is effectively the first full trading session for the market to price in the news. Analysts have previously suggested a “substantial re-rate” is likely on approval — watch opening volume and price action closely for confirmation.
Bull Case: A seven-year regulatory monopoly in a clinically recognized but previously unavailable market gives Telix genuine pricing power, and the company’s existing commercial infrastructure for its prostate-imaging franchise should accelerate Pixclara’s rollout.
Bear Case: The FDA rejected this same drug once before in 2025 and required additional evidence, and translating regulatory approval into meaningful, fast-growing sales still requires real-world physician adoption that isn’t guaranteed to happen quickly.
Forecast: Watch for management commentary on Pixclara’s initial commercial rollout timeline — the speed of that launch, more than the approval itself, will determine how much of a re-rating this ultimately produces.
6. The Elmet Group (ELMT) | Closed at $21.41 | Still Riding the $450 Million Wave
Analysts Have Yet to Fully Catch Up to Monday’s News
Elmet remains in sharp focus as Wall Street continues digesting the scale of its new government-backed defense investment.
Full Data & Snapshot:
| Metric | Value |
|---|---|
| Last Close | $21.41 |
| 52-Week High | $22.51 |
| DoW Investment | $450M |
| DLA Contract Ceiling | Up to $2B |
| Pre-News Canaccord Target | $21 (already stale) |
Why It’s in Focus: Elmet’s management held an investor call Monday detailing the structure of its $450 million Department of War investment and up to $2 billion Defense Logistics Agency contract, but formal analyst price-target revisions have yet to catch up to Monday’s 32% surge. Tomorrow could bring the first wave of updated coverage now that the market has had a full day to digest the deal’s structure, including the government’s warrant position for up to 19.9% of common stock.
Technicals: A confirmed close above the $22.51 52-week high would put the stock in fresh territory since its founding; support sits at $19.50–$20.00, roughly last week’s pre-announcement trading range.
Bull Case: Multi-year, government-backed revenue visibility from both the equity investment and the DLA contract ceiling gives Elmet unusually durable demand certainty for a company of its size.
Bear Case: The government’s warrant position represents real future dilution that could weigh on the stock once initial enthusiasm fades and analysts fully price in the share-count impact.
Forecast: Watch for the first round of formal analyst price-target increases — a cluster of upward revisions tomorrow would confirm Wall Street sees this as a durable re-rating rather than a one-day pop.
7. ACV Auctions (ACVA) | Closed at $10.41 | Still the Cleanest Trade on the List
A Merger-Arb Story That Doesn’t Care About the Fed
ACV Auctions remains one of the few names on this list genuinely insulated from tomorrow’s macro drama, trading almost exactly at its agreed buyout price.
Full Data & Snapshot:
| Metric | Value |
|---|---|
| Last Close | $10.41 |
| Deal Price | $10.50/share cash |
| Acquirer | Copart, Inc. |
| Deal Value | ~$1.9B |
| Expected Close | End of 2026 |
Why It’s in Focus: With Copart’s all-cash acquisition still pending regulatory review, ACVA’s tight trading range makes it a useful, largely Fed-decision-immune name to watch — any movement in the stock is far more likely to reflect deal-specific news than macro headlines.
Technicals: Resistance is effectively capped at $10.50 absent a competing bid. Support sits at $10.00–$10.20, where arbitrage funds have been active buyers.
Bull Case: This is close to a locked-in return for anyone holding below $10.50, with a signed, unanimously-approved deal structure limiting downside risk.
Bear Case: Extended antitrust review remains the primary risk that could delay or complicate the deal timeline regardless of broader market conditions.
Forecast: Expect continued tight-range trading — this is the rare name on this list where tomorrow’s Fed decision is essentially irrelevant to the investment case.
8. Ocean Power Technologies (OPTT) | Split-Adjusted Trading Enters Day Three
The Reverse Split’s Real Test Continues
Ocean Power Technologies heads into its third day of split-adjusted trading, with each passing session providing more clarity on whether the reset has actually stabilized the stock.
Full Data & Snapshot:
| Metric | Value |
|---|---|
| Split Ratio | 1-for-30, effective Sept. 14, 2026 |
| Pre-Split Close | $0.107 |
| Going-Concern Warning | Active |
| Strategic Alternatives Review | Ongoing |
Why It’s in Focus: Two sessions into split-adjusted trading, tomorrow will help confirm whether OPTT has found a stable footing or continues drifting as the market weighs its active going-concern warning against its ongoing U.S. Army coastal-testing demonstration for its WAM-V unmanned surface vessel platform.
Technicals: With limited historical data on the new share count, watch for three consecutive stable-to-higher closes as a genuine signal of post-split stabilization.
Bull Case: A credible defense-testing pathway with the U.S. Army offers non-dilutive upside if it converts into a formal contract.
Bear Case: A disclosed going-concern warning remains a serious red flag that a reverse split alone historically does very little to resolve.
Forecast: This remains a name to watch purely for stabilization signals rather than upside catalysts — three straight steady sessions would be a meaningfully positive development at this point.
9. HUB Cyber Security (HUBC) | Split-Adjusted Trading Enters Day Three
Watching for Any Sign This Time Is Different
HUB Cyber Security’s third reverse split in roughly a year faces its most telling test yet as split-adjusted trading enters its third session.
Full Data & Snapshot:
| Metric | Value |
|---|---|
| Split Ratio | 1-for-25, effective Sept. 14, 2026 |
| New CUSIP | M6000J309 |
| Shares Outstanding (Post-Split) | ~1.8M |
| Prior Splits (Past Year) | 1-for-15 (Jan.), 1-for-50 (Apr.) |
Why It’s in Focus: With two prior reverse splits in the past year both failing to produce lasting stability, tomorrow’s session is an important data point in determining whether this latest capital-structure reset behaves any differently. Any operational updates from the company’s confidential-computing business would carry significant weight given how thin the stock’s credibility currently is after repeated splits.
Technicals: With a new CUSIP and share count, watch for three consecutive stable-to-higher closes as the baseline signal that this split is holding better than its predecessors.
Bull Case: Regaining Nasdaq Market Value compliance earlier this year shows at least incremental progress on the listing-standards front.
Bear Case: A third reverse split within twelve months is about as clear a signal as the market gets that underlying business problems remain unresolved.
Forecast: The burden of proof remains entirely on HUBC — the market has seen this movie twice before and isn’t likely to reward a third rerun without concrete operational improvement.
10. Moelis & Company (MC) | A Boutique Bank Feeling the Dealmaking Chill
When a Wall Street Giant Sneezes, Boutique Banks Catch Cold
Moelis & Company and its boutique investment-banking peers found themselves swept into Monday’s broader financial-sector selloff after a mega-bank’s blunt guidance warning rattled the entire dealmaking industry.
Full Data & Snapshot:
| Metric | Value |
|---|---|
| Sector | Investment banking / M&A advisory |
| Catalyst Origin | Bank of America Q3 guidance warning |
| BAC Guided IB Fee Decline | More than 10% YoY |
| BAC Share Move (Monday) | −5.17% to −5.7% |
Why It’s in Focus: Bank of America CEO Brian Moynihan’s blunt comments at the Barclays Global Financial Services Conference — guiding Q3 investment banking fees down more than 10% year-over-year and flat trading revenue — sent shockwaves through the entire capital-markets complex, dragging peers including Goldman Sachs, Citigroup, and Wells Fargo lower alongside boutique advisory shops like Moelis. As a pure-play M&A and restructuring advisory firm without a trading desk to offset weaker dealmaking, Moelis is arguably more directly exposed to the “10% industry-wide decline” Moynihan specifically cited than any diversified mega-bank.
Technicals: With Wednesday’s Fed decision layered on top of this fresh dealmaking-slowdown scare, watch for continued sector-wide weakness in boutique advisory names if the Fed’s hawkish tone reinforces concerns about a slower M&A environment heading into year-end.
Bull Case: Boutique advisory firms like Moelis carry no trading-desk exposure, meaning a slowdown limited specifically to capital-markets and trading revenue — as Moynihan described — may not fully translate to Moelis’s core M&A advisory business.
Bear Case: If Moynihan’s “broad-based slowdown in the investment banking market” reading is accurate industry-wide, pure-advisory shops with less revenue diversification than mega-banks could see an even sharper proportional hit to earnings.
Forecast: Watch how boutique advisory names trade relative to the big banks tomorrow — meaningful outperformance would suggest the market sees Moynihan’s warning as bank-specific rather than an industry-wide dealmaking freeze.
At a Glance: Stocks to Watch Tomorrow
| Rank | Stock (Ticker) | Recent Price | Why It’s in Focus |
|---|---|---|---|
| 1 | Redwood Trust (RWT) | ~$3.77 | Purest Fed-decision trade on the list |
| 2 | IREN Limited (IREN) | $43.83 | JPMorgan double upgrade vs. sector sentiment |
| 3 | MARA Holdings (MARA) | ~$11.00 | Double Fed exposure via Bitcoin + financing |
| 4 | Super Micro Computer (SMCI) | $37.33 | AI-slowdown fears meet Fed jitters |
| 5 | Telix Pharmaceuticals (TLX) | N/A | Fresh FDA approval for Pixclara |
| 6 | The Elmet Group (ELMT) | $21.41 | Analyst targets catching up to $450M deal |
| 7 | ACV Auctions (ACVA) | $10.41 | Fed-immune merger-arb trade |
| 8 | Ocean Power Technologies (OPTT) | N/A | Day 3 of reverse split |
| 9 | HUB Cyber Security (HUBC) | N/A | Day 3 of reverse split (3rd in a year) |
| 10 | Moelis & Company (MC) | N/A | Boutique bank caught in dealmaking chill |
Follow TNN for daily stock market news and financial news today.
Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss, and small-cap, high-volatility, and recently split stocks like those featured above carry elevated risk. Stock prices, percentage moves, technical levels, and market data cited reflect figures available at the time of publication and are subject to change as trading continues. Analyst price targets and ratings are third-party estimates and do not guarantee actual results. Always complete independent due diligence prior to executing equity trades.
About The Author
